Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele

Cited by (2,225)

Items 2,101–2,200 of 2,225

1. Elexacaftor-tezacaftor-ivacaftor for individuals with residual CFTR activity: an open-label, nonrandomized clinical trial
   Rachel W. Linnemann, George Marty Solomon, Adrianna Lynn Westbrook, Rachel Rich, Ashleigh Streby, Eric Hunter, András Rab, Shasha Bai, Carmel M. McNicholas, Jeong S Hong et al. · 2026 · Annals of the American Thoracic Society
2. Real‐World Clinical Outcomes of Lumacaftor‐Ivacaftor or Tezacaftor‐Ivacaftor Therapy in Children With Cystic Fibrosis Homozygous for Phe508del
   Nele Aerssens, François L. Vermeulen, Mieke Boon, Marijke Proesmans · 2026 · Pediatric Pulmonology
3. ORIGIN-1 trial: study protocol for an organoid-guided N-of-1 trial evaluating CFTR modulator response in cystic fibrosis with rare non-F508del mutations
   Lorena Rodrigues Sabino, Gerard E. Kaiko, Douglas J. Dorahy, Thomas M Goodsall, Adam Jaffé, André Schultz, Shafagh A. Waters, Dane Cook, Harvey Kok, Koliarne Tong et al. · 2026 · Trials
4. Nutrition Therapy for Cystic Fibrosis–Related Diabetes
   Michelle McDonagh · 2026 · American Diabetes Association eBooks
5. Real‐Life Experience With a Generic Formulation of Elexacaftor/Tezacaftor/Ivacaftor in Patients With Cystic Fibrosis With Responding Variants
   Alejandro Teper, Viviana Rodríguez, Silvina Lubovich, S Zaragoza, E. Rodriguez Novoa, Facundo García‐Bournissen · 2026 · Pediatric Pulmonology
6. From phenotype to molecular characterization: A case report of a novel CFTR gene variant, c.4345_*486delinsTTG
   Francisco Martínez Bugallo, Gema García-de la Rosa, Nayra Pérez‐Delgado, Carol Prieto-Morin · 2026 · Pneumon
7. Assessment of CFTR Dysfunction and Responsiveness to CFTR Modulators in COPD Bronchial Air–Liquid Interface Cultures
   Nikhil T Awatade, Kurtis F. Budden, Prabuddha S. Pathinayake, Andrew T. Reid, Kristy Nichol, Peter A. B. Wark · 2026 · International Journal of Molecular Sciences
8. Zystische Fibrose und Bronchiektasen: Potenzial und Grenzen der Modulatoren
   Carsten Schwarz, Lilith Bechinger · 2026 · Pneumo News
9. In Utero Molecular-Targeted Drug Therapies: Translational Principles, Pharmacologic Considerations, and Emerging Clinical Applications
   Akihiro Hasegawa, Ehsan Rojhani, Ahmed Hashem Fathallah, Rodrigo Ruano, Alireza Abdollah Shamshirsaz · 2026 · Journal of Clinical Medicine
10. SPL84 and Trikafta® exhibit comparable and additive effects in patient-derived HBE cells carrying the 3849+10kb C→T/F508del CFTR variants
    Yi Cheng, Yifat S. Oren, Jan Harrington, Aurélie Hatton, Efrat Ozeri-Galai, C. Stampfer, Tamar Mordechai, Ofra Barchad-Avitzur, Gili Hart, Kevin J. Coote et al. · 2026 · Journal of Cystic Fibrosis
11. Persistence of large P. aeruginosa aggregates despite reduced airway burden in people with cystic fibrosis on CFTR modulator therapy
    Amanda J. Morris, Shafinaz Eisha, Yvonne C. W. Yau, Sara Goel, Michelle Shaw, William H. DePas, Isaac Martin, Arunan Selvarajah, Mellissa Gaudet, Elizabeth Tullis et al. · 2026 · Journal of Cystic Fibrosis
12. Suboptimal vaccine coverage for preventable respiratory infections in children with cystic fibrosis in the Cystic Fibrosis Regional Reference Centre of Tuscany: Need for improving preventive strategies
    Federico Forgione, Clementina Canessa, Giovanni Taccetti, Cristina Fevola, Chiara Azzari, Silvia Ricci, Vito Terlizzi · 2026 · Human Vaccines & Immunotherapeutics
13. Cystic Fibrosis: Modern Diagnostic and Therapeutic Advances from Molecular Pathogenesis to Multidisciplinary Management
    Li-qin Ke, Lijun Guan, Yiyao Bao, Chao Tang · 2026 · Genes
14. Nadir Hastalıklarda Kalıtım Modelleri: Moleküler Patogenez, Genotip–Fenotip İlişkileri ve Hassas Tıp Perspektifleri
    Naciye Selcen Bayramcı, Dilan Yavuz · 2026 · Özgür Yayınları eBooks
15. Patient-Reported Health-Related Quality of Life in Romanian Patients with Cystic Fibrosis in the Era of Highly Effective CFTR Modulator Therapy: A National Cross-Sectional Mixed-Methods Survey
    Cristian Marinău, Cristian Nicolae Sava, Alin Iuhas, Ioana Mihaiela Ciucă, Liviu Laurentiu Pop, Mihai Craiu, Zsolt Futaki, Ariana Szilágyi, Alexandru Jurca, Claudia Maria Jurca · 2026 · Journal of Clinical Medicine
16. Cystic fibrosis nutrition: Addressing emerging trends following the 2024 ESPEN-ESPGHAN-ECFS guidelines. Expert opinion recommendations
    Chris Smith, Sarah Collins, Carla Colombo, Dimitri Declercq, Tamarah Katz, Daina Kalnins, Isabelle Scheers, Daniel Gavin Peckham, J. Snowball, Michael A. Wilschanski · 2026 · Journal of Cystic Fibrosis
17. L’impatto di Elexacaftor/Tezacaftor/Ivacaftor sulla storia clinica della fibrosi cistica in età pediatrica: case series
    Enza Montemitro, Parisi G. F., S. Leonardi, A. Boni, Renato Cutrera · 2026 · Pneumologia Pediatrica
18. Specialized pro-resolving mediators regulate in vitro human airway epithelial resistance to Aspergillus fumigatus
    Khadeeja Adam Sy, Isabel Valsecchi, Maëlle Briottet, Marie Vaudin, E.F. Barny, M. El Moustaphaoui, Françoise Botterel, Valérie Urbach · 2026 · Mucosal Immunology
19. Dynamic Inspiratory Muscle Strength in Children with Cystic Fibrosis: Implications for Preoperative Assessment
    Seyyedeh Narjes Ahmadizadeh, Hasan Shamsi, Saeed Sadr, Maryam MirJafari · 2026 · Journal of Cellular & Molecular Anesthesia
20. Case Report: When access is limited: using CYP3A4 inhibition to maintain clinical benefit from elexacaftor/tezacaftor/ivacaftor
    Keirran Hiscock, Michelle Wood, Ellie Johnson, Daniel B. Smith, Ieuan Evans · 2026 · Frontiers in Pharmacology
21. Long-term safety and efficacy of lumacaftor/ivacaftor in children aged ≥12 months of age with cystic fibrosis: a 96-week open-label study
    Edith T. Zemanick, Susanna A. McColley, Rachel W. Linnemann, Jonathan H. Rayment, William T. Harris, Bonnie W. Ramsey, Edward F. McKone, Elizabeth Tullis, Marcus Alexander Mall, Jennifer L. Taylor‐Cousar et al. · 2026 · ERJ Open Research
22. Meaningful Criteria to Persons Living With Cystic Fibrosis and Their Healthcare Providers in Helping Determine Adjustments to Routine Clinical Follow‐Up
    William R. Hunt, Christian Merlo, Ashley Keller, Karen Lowe, Kristin A. Riekert, James D. Finklea · 2026 · Pediatric Pulmonology
23. Residual disease activity in cystic fibrosis lung disease: implications for clinical management and research
    Andrea Gramegna, Gianmarco Putti, Gianfranco Alicandro, Marcus Alexander Mall, Francesco Blasi · 2026 · American Journal of Respiratory and Critical Care Medicine
24. Cystic Fibrosis and Adolescent and Young Adult Reproductive Healthcare
    Madison Martinez, Maya Albanowski, Traci M. Kazmerski · 2026 · Springer eBooks
25. The role of sweat chloride in determining CFTR protein restoration in people with cystic fibrosis
    Edith T. Zemanick, Simon Y. Graeber, Carlo Castellani, Garry R. Cutting, Isabelle Fajac, Michael W. Konstan, Rachel W. Linnemann, Edward F. McKone, Adam Metcalf, George Marty Solomon et al. · 2026 · The Lancet Respiratory Medicine
26. Effects of elexacaftor/tezacaftor/ivacaftor on the nasal microbial metagenome in cystic fibrosis
    T.L. Hertramph, Marie Dorda, Sophia Theres Pallenberg, Annette Sauer‐Heilborn, Felix C. Ringshausen, Matthias Steglich, Gesine Hansen, Burkhard Tümmler, Lutz Wiehlmann, Ilona Rosenboom et al. · 2026 · Microbiology Spectrum
27. Clinical and biochemical response to elexacaftor/tezacaftor/ivacaftor in a patient with the rare L927P/N1303K CFTR genotype
    Sayed Alwadaei, Emily Chellam, Nicki Allsup, Dejene Shiferaw · 2026 · Respiratory Medicine
28. Hypoglycemia as a new challenge in traetment with modulatory therapy in patients with cystic fibrosis
    Olivera Ljuboja, Gordana Bukara-Radujković, Daliborka Tadić · 2026 · Respiratio
29. Aligning clinical care with consumer priorities: an adult cystic fibrosis centre experience of co‐designing a model of care
    Shanal Kumar, Vanessa Moore, Daniel B. Smith, Angela G. Matson · 2026 · Internal Medicine Journal
30. The prevalence of obstructive sleep apnea-hypopnea syndrome in patients with cystic fibrosis: An updated systematic review and meta-analysismeta-analysis
    Jun Zeng, Yu Hua, Jia Liu, Jiaqing Jiang, Li J, Jie He · 2026 · Medicine
31. Normalization of total bilirubin after switch from elexacaftor/tezacaftor/ivacaftor to vanzacaftor/tezacaftor/deutivacaftor in patients with cystic fibrosis and Gilbert’s syndrome
    Susanne Naehrig, M. Breuling · 2026 · Journal of Cystic Fibrosis
32. Cystic Fibrosis Newborn Screening: Cost Trajectory as a Marker to Improve Health Outcomes
    Ambika Shenoy, KW Southern · 2026 · Pediatric Pulmonology
33. Real-world experience with a generic formulation of elexacaftor/tezacaftor/ivacaftor in children with cystic fibrosis
    María Macarena Oneglia, Hilda Giugno, Ariela Agustinho, P. Plubatsch, Claudio Castaños · 2026 · Journal of Cystic Fibrosis
34. Epithelial Chloride and Bicarbonate Transport in Intestinal Barrier Failure: A Molecular Target-Validation Assessment of CFTR and SLC26A3/DRA in Inflammatory Bowel Disease
    Yohan Seo · 2026 · International Journal of Molecular Sciences
35. Three-year outcomes of elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis: A real-world study
    Ester Zamarrón de Lucas, Clara Crespo Catalán, Belén Romero Campos, Belén Sanz-Sanjosé, María Longás Ouzzine, C Ladrón de Guevara, Rodolfo Álvarez-Sala Walther, María Concepción Prados · 2026 · Medicina Clínica (English Edition)
36. Current diabetes therapy and use of diabetes technology in people living with cystic fibrosis-related diabetes (CFRD): Insights from the DPV network
    Thomas Hörtenhuber, Stefanie Schmid, Claudia Boettcher, Silke Herrlinger, Mareike Niemeyer, Martin Tauschmann, Reinhard Walter Holl, Nicole Prinz · 2026 · Journal of Cystic Fibrosis
37. Exploring the lived experiences of individuals with cystic fibrosis after the implementation of elexacaftor/tezacaftor/ivacaftor for treatment
    Alyssa Riggle, Annelise Page, Erica A. Roesch, Marsha Michie, Rebecca J. Darrah · 2026 · Therapeutic Advances in Respiratory Disease
38. EASE-CF: dietitian-led weight-loss intervention for adults with cystic fibrosis and excess weight: protocol for a feasibility randomised controlled trial
    J. Snowball, Amanda Adler, Phillippa J. Lally, Nick P. Talbot, Emma Hedley, Dimitrios A. Koutoukidis · 2026 · BMJ Open Respiratory Research
39. Aspergillus fumigatus coinfection facilitates Pseudomonas aeruginosa chronicity within an ex-vivo pig lung model
    Aaron Curtis, David A. Fitzpatrick, Freya Harrison, Kevin A. Kavanagh · 2026 · Microbiology
40. Subgroup analysis using exchangeability probabilities
    Shannon D. Thomas, Alexander M. Kaizer · 2026 · Contemporary Clinical Trials
41. Real-world population pharmacokinetic modeling of elexacaftor, tezacaftor, and ivacaftor
    Alexandra K. Kunzelmann, S. Naehrig, Christina Shad, M. Breuling, Melanie Goetschke, Katharina Habler, O Sommerburg, J Behr, LM Schatz, Johannes Starp et al. · 2026 · Journal of Cystic Fibrosis
42. Real-world efficacy, safety and heterogenicity of efficacy of elexacaftor-tezacaftor-ivacaftor in younger children (6-11 years old) with cystic fibrosis
    Shahid Ijaz Sheikh, Melissa Holtzlander, Mariah Eisner, Courtney A. Gushue, SABRINA K PALACIOS, Eric S. Mull, Sehyr Imran, Kavitha S. Kotha, Karen S. McCoy · 2026 · Respiratory Medicine
43. Polymicrobial Extracellular Vesicles Reduce the Innate Immune Response of Human Cystic Fibrosis Bronchial Epithelial Cells
    Lily A. Charpentier, Roxanna Barnaby, Carolyn Roche, Byoung-Kyu Cho, Prashant Kaushal, Young Ah Goo, Brad Vietje, Douglas J. Taatjes, Alix Ashare, Fabrice Jean-Pierre et al. · 2026 · Journal of Extracellular Biology
44. DNA sequencing for microbial surveillance in cystic fibrosis airways: advances, challenges, and clinical translation
    Jessica A. P. Carlson-Jones, Thomas R. Goddard, Bhavya Nalagampalli Papudeshi, Vijini Mallawaarachchi, Katrine Whiteson, Morgyn S. Warner, Judith M. Morton, Hubertus P. A. Jersmann, Robert Alan Edwards · 2026 · Clinical Microbiology Reviews
45. Revision Endoscopic Sinus Surgery in Cystic Fibrosis With Chronic Rhinosinusitis: Before and After Cystic Fibrosis Transmembrane Conductance Regulator Triple Modulator Therapy
    Brian P. Kinealy, Anthony A. Mangino, Jacob Dylan Johnson, Jasarae McKinney, Michael Anstead, Brett T. Comer · 2026 · American Journal of Rhinology and Allergy
46. Targeted Therapy for Restoring CFTR Activity: From Experimental to Clinical Features
    Sara Allushi, Mariarita Virgulti, Giovanna Blaconà, Giampiero Ferraguti, Adriana Eramo, Marco Lucarelli · 2026 · International Journal of Molecular Sciences
47. Clinical characteristics and outcomes of people with cystic fibrosis with homozygous minimal function genotypes compared to those with F508del/minimal function genotypes
    Michael W. Konstan, Brandon Lumsden, Prema R. Menon, Maral DerSarkissian, Megan S. Rice · 2026 · Respiratory Medicine
48. Cystic fibrosis: insights from zebrafish models
    Sarahdja Cornélie, Laure Yatime, Georges Lutfalla, Stephen A. Renshaw, Audrey Bernut · 2026 · Disease Models & Mechanisms
49. Late-Diagnosed Cystic Fibrosis in an Octogenarian With an Atypical Phenotype of Pancreatic Sufficiency and Preserved Pulmonary Function
    Brenda Hranec, Luke A. Hudson, Daniel Layish · 2026 · Cureus
50. Adverse effects of vanzacaftor-tezacaftor-deutivacaftor in a cystic fibrosis population: A case series
    Jordan L. Saag, Sinead O’Bryant, K Amos, O Marett, Brian Garcia, Stefanie Krick · 2026 · Respiratory Medicine Case Reports
51. Elastic Fibers in the Pathogenesis of Cystic Fibrosis: Mechanisms, Consequences, and Therapeutic Implications
    Jerome O. Cantor · 2026 · Life
52. Efficacy and safety of switching within one international non-proprietary name (elexacaftor/tezacaftor/ivacaftor) in children with cystic fibrosis: clinical experience of transition from Trikafta to Trilexa
    D.F. Sergienko Sergienko, O. I. Golubtsova, Elena Alexandrovna Enina · 2026 · ASTRAKHAN MEDICAL JOURNAL
53. Triple potentiator combinations increase the functional correction of several CFTR gating mutants
    Guido Veit, Christian Vaccarin, Marton A. Simon, Haijin Xu, Houriyeh Hajizadeh, Tina He, Adriana Chilin, Elias Matouk, László Csanády, Giovanni Marzaro et al. · 2026 · npj Drug Discovery.
54. Cystic fibrosis transmembrane conductance regulator modulator therapy and lived experiences in South Africa: A mixed-methods study
    Brenda May Morrow, Janine Verstraete, S. Thistlewhite, Carese Abrahams, Nkosi TB, Tyra Donnelly, Dalziel Kennedy, Marco Zampoli · 2026 · South African Journal of Physiotherapy
55. Precision therapy reduces the risk of diabetes in people with cystic fibrosis-related diabetes
    Samar E. Atteih, Karen S. Raraigh, Malinda Wu, Joseph Michael Collaco, Scott M. Blackman · 2026 · medRxiv
56. Combining Gene Therapy with Current Modulator Treatments for Cystic Fibrosis: A Promising Area of Research
    Xavier Buin, Rosy Ghanem, Ines Pankonien, Frédéric Becq, Margarida Duarte Amaral, Tristan Montier · 2026 · Pharmaceutics
57. Prenatal CFTR modulator therapy and fetal meconium ileus in cystic fibrosis: a systematic review and individual patient data meta-analysis
    Vincenzo Giannicola Menditto, Giovanni Pomponio, Nicole Caporelli, Marica Bordicchia, Alessandra Boni, Marco Rocchi, Giacomo Menditto, Benedetta Fabrizzi · 2026 · Journal of Cystic Fibrosis
58. Once-daily hypertonic saline inhalation and airway clearance techniques in children with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor: a prospective multicentre study
    Marcus Svedberg, Christina Krantz, Henrik Imberg · 2026 · Journal of Cystic Fibrosis
59. Присоединение FEN1 к PEmax через короткий аминокислотный линкер существенно повышает эффективность праймированного редактирования
    2026
60. Case Series of Sustained Fluid‐Associated Weight Gain Following Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulator Therapy
    Emma M. Tillman, Arina Lazutina, Ross C. Robinson, Abi Colwell, Cynthia D. Brown · 2026 · Pediatric Pulmonology
61. Anti-inflammatory and phosphorylation effects of CFTR modulator triple therapy in cystic fibrosis
    Hiran C. Selvadurai, Velda Xinying Han, Brooke A. Keating, Mark Graham, Nader Aryamanesh, Lee L. Marshall, Suat Dervish, Xianzhong Lau, Ruwani Dissanayake, Stephen I. Alexander et al. · 2026 · iScience
62. Association of depressive symptoms with sweat chloride variability and medication possession ratio during long-term Elexacaftor/Tezacaftor/Ivacaftor therapy in adolescents and young adults with cystic fibrosis
    Michael Lorenz, Mariya Pavlova, K. Erler, Anika Nader, Anne Moeser · 2026 · Frontiers in Pediatrics
63. Comparative Alignment of CFTR2 and CFTR-France Classifications with a Turkish Cystic Fibrosis Referral Cohort
    Mustafa Tarık Alay, Filiz Özdemir, Deniz Ağırbaşlı, Mehmet Seven, Aysel Kalaycı Yiğin · 2026 · International Journal of Molecular Sciences
64. Bridging the Gap in Eastern European Cystic Fibrosis Care: How Newborn Screening and Advanced CFTR Modulation Shape the Clinical Landscape in Western Romania
    Cristian Marinău, Cristian Nicolae Sava, Alin Iuhas, Ioana Mihaiela Ciucă, Liviu Laurentiu Pop, Larisa Niulaș, Ariana Szilágyi, Alexandru Jurca, Claudia Maria Jurca · 2026 · Children
65. Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Patients With Severe Lung Disease Carrying Previously Ineligible CFTR Mutations
    Laura Carrasco Hernández, Rosa María Girón Moreno, Amparó Solé, Concepción Prados Sánchez, Cristina Ramos Hernández, María Victoria Girón, Rosa Mar Gómez Punter, María José Selma-Ferrer, Gabriel Olveira, Ester Zamarrón et al. · 2026 · Open Respiratory Archives
66. Lung function trajectories in children with cystic fibrosis aged 3-17 years: impact of elexacaftor-tezacaftor-ivacaftor on lung function
    Brett Paul Dyer, Maddy Deery, Rebecca Heyman, Paul D. Robinson, Claire Elizabeth Wainwright, Peter David Sly, Robert Stuart Ware, Tamara L. Blake · 2026 · medRxiv
67. Acute kidney injury after aminoglycoside exposure in two cystic fibrosis patients receiving triple CFTR modulator therapy
    Deslais Martin, Etienne Novel-Catin, Nove-Josserand Raphaële, Denis P. Fouque, I. Durieu · 2026 · Journal of Nephrology
68. Changes in Aerobic Fitness Following Initiation of CFTR Modulator Therapy: A Systematic Review and Meta‐Analysis
    Ingrid Silveira de Almeida, Fernanda Maria Vendrusculo, Mariana Severo da Costa, Márcio Vinı́cius Fagundes Donadio · 2026 · Pediatric Pulmonology
69. Global Landscape of SLC37A4 Variants and Their Potential Amenability to Pharmacological Chaperone Therapy in Glycogen Storage Disease Type Ib
    Anita Skakić, Kristel Klaassen, Marina Andjelković, Jovana Komazec, Marina Parezanovic, Nikola Jocic, Maja Djordjevic, Maja Stojiljković · 2026 · Sci
70. Delayed diagnosis of cystic fibrosis: clinical burden and missed opportunities in a cohort from Rio de Janeiro, Brazil
    Renata Wrobel Folescu Cohen, Tânia Wrobel Folescu, Leonardo Yllel Da Rocha, Monica Muller Taulois, Patrícia Fernandes Barreto Machado Costa, Raphael Freitas Jaber De Oliveira · 2026 · Respiratory Research & Clinical Practice
71. Case report end-stage cystic fibrosis with fatal outcome in two siblings from a Chinese family: a 15-year diagnostic odyssey
    Yuelin Shen, Qionghua Chen, Haiming Yang · 2026 · Frontiers in Pharmacology
72. Behandlung der Mukoviszidose mit CFTR-Modulatoren
    Mirjam Stahl, Marcus Alexander Mall · 2026 · Monatsschrift Kinderheilkunde
73. Mucoviscidose de l’enfant
    A. Le, Emmanuelle Girodon, Isabelle Sermet‐Gaudelus · 2026 · Encyclopédie médico-chirurgicale. Pneumologie
74. Thermophysiological and perceptual responses to exercise heat stress in people with cystic fibrosis on Elexacaftor/Tezacaftor/Ivacaftor
    Lauren Clayton, Jo Corbett, Anthony I. Shepherd, Heather C. Massey, Don S. Urquhart, Neil Maxwell, Gary James Connett, Mark Ivan Allenby, Julian P. Legg, Thomas W V Daniels et al. · 2026 · Experimental Physiology
75. Assessing the impact of elexacaftor/tezacaftor/ivacaftor on work productivity and activity impairment in people living with cystic fibrosis in Canada
    Grace G. Kim, Taryn Wong, Jonathan Rayment, Lara Bilodeau, Elizabeth Tullis, Larry C. Lands, Winnie M. Leung, Grace Y. Lam, Felix A. Ratjen, Bradley S. Quon · 2026 · Journal of Cystic Fibrosis
76. Evaluating Dietary Assessment Methods in Adults with Cystic Fibrosis in the Modulator Era: A Comparison of Food Frequency Questionnaires and Three-Day Food Diaries
    Cian Greaney, Caoimhe Egan, Deanna Kenny, Sarah Tecklenborg, Ciara Howlett, Karen Cronin, Clodagh Landers, Mary Connolly, Derbhla O’Sullivan, Katie Robinson et al. · 2026 · Nutrients
77. The Cost of Control: Financial and Administrative Burdens of Limited Distribution Network Changes in Cystic Fibrosis
    Brittany A. Wright, Cameron J. McKinzie, Charissa W. Kam, Casey R. Tak, Lynnsey M. Knockel, Julie Langhorst, Rebecca S. Pettit, Lynda Roe, B. Simonson, Hilary Vogt et al. · 2026 · Pediatric Pulmonology
78. Bridging the divide between health economics and outcomes research and biomedical investment: reflections from a health economist working in venture capital
    Richard Z. Xie · 2026 · Journal of Comparative Effectiveness Research
79. Kinésithérapie et trouble ventilatoire obstructif, en phase stable : traitements et prise en charge
    Guillaume Prieur, Tristan Bonnevie, Francis‐Edouard Gravier, Yann Combret, C. Médrinal · 2026 · EMC - Kinésithérapie - Médecine physique - Réadaptation
80. Maternal and fetal outcomes associated with CFTR modulator use during pregnancy: a scoping review
    Zihanjiao Wang, Rasa Ruseckaite, Aleksandar Dobric, Danni Li, Zhengzheng Liu, Peter A. B. Wark, André Schultz, Imogen Felton, Siân Bentley, Jane Carolyn Davies et al. · 2026 · European Respiratory Review
81. Beyond Tuberculosis: Late Diagnosis of Cystic Fibrosis in an Adolescent with Bronchiectasis and Recurrent Pseudomonas aeruginosa Isolation: A Case Report
    Oana Mariana Mihailov, Valerii Luțenco, Lavinia Țocu, Raul Mihailov, Loredana Stavăr-Matei, George Țocu · 2026 · Diagnostics
82. Functional and Compositional Shifts in Lung and Gut Microbiota after One Year of Treatment with Highly Effective CFTR Modulators in Cystic Fibrosis
    Natalia Bastón-Paz, Carmen García-Durán, Doğukan Bayraktar, Esther Palacios, Ana Moreno‐Blanco, Janetta Top, María Garriga-García, Luís Máiz, Saioa Vicente‐Santamaría, Antonio Oliver et al. · 2026 · Archivos de Bronconeumología
83. The New Landscape of Cystic Fibrosis in the Era of Highly Effective Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy.
    Anna Wołkowicz, Katarzyna Walicka‐Serzysko, Justyna Milczewska, Dorota Sands · 2026 · PubMed Central
84. Clinical and research perspectives on pharmacogenetics and theratyping in pulmonology: A narrative review
    Aleksandra Jezela‐Stanek · 2026 · Sage Open Chronic Disease
85. The effectiveness of a generic CFTR-modulator in a prolonged multicenter study
    E. Kondratyeva, Anna Y. Voronkova, Elena Kestutisovna Zhekaite, Victor Kovalev, А. В. Орлов, O. G. Pyaterkina, Ekaterina Aleksandrovna Ovsyannikova, Рыбалкина Марина Георгиевна · 2026 · Meditsinskiy sovet = Medical Council
86. Late-Diagnosed Cystic Fibrosis with Co-Occurring CFTR 3849+10kbC>T and 5T Variants: A Case Report
    Paula Popovici, Adriana Mihai, Lăcrămioara Ionela Butnariu, Razvan Mihai Popovici, Alina Mariela Murgu, Elena Țarcă, Ileana Katerina Ioniuc, Tania Elena Rusu, Dana-Teodora Anton-Păduraru, Oana Raluca Temneanu · 2026 · Journal of Clinical Medicine
87. Convergent strategies for nanobody-mediated inhibition of an epoxide hydrolase
    Adam R. Simard, Noor M Taher, Kathryn S. Beauchemin, Akaash Kumar Mishra, Andrew P. Hederman, Thomas H. Hampton, Natalia Vasylieva, Christophe H.P. Morisseau, Margaret E. Ackerman, Dean R. Madden · 2026 · Journal of Structural Biology X
88. Protein rheostasis: quality control in metastable proteomes
    Michele Vendruscolo · 2026 · Philosophical Transactions of the Royal Society B Biological Sciences
89. Vanzacaftor/tezacaftor/deutivacaftor partially restores CFTR function of the L467F;F508del complex allele in primary nasal epithelial cells
    Jasmin Berger, Anita Balázs, Rebecca Dalferth, Katharina Schütz, Anna‐Maria Dittrich, Valentina Cvejoska Cholakovska, Stojka Fushtik, Elena Krsteska, Stephanie Thee, Mirjam Stahl et al. · 2026 · Journal of Cystic Fibrosis
90. Real-world outcomes of elexacaftor/tezacaftor/ivacaftor in a cohort of children and adolescents with cystic fibrosis in Brazil
    Renata Wrobel Folescu Cohen, Paloma Fernandes Coelho, Leonardo Yllel Da Rocha, Julia Vieira da Cunha Moreira, Natalia Barboza, Katty Anne Carvalho Marins, Viviane Mauro Corrêa Meyer, Patrícia Fernandes Barreto Machado Costa, Tânia Wrobel Folescu · 2026 · Respiratory Research & Clinical Practice
91. CFTR Functional Rescue and Heterogeneous Clinical Outcomes Following Elexacaftor/Tezacaftor/Ivacaftor Therapy in People with Cystic Fibrosis Carrying the W1282R Variant
    E. Kondratyeva, Anna Sergeevna Efremova, Yuliya L. Melyanovskaya, Elena Zhekaite, Maria Sapelnikova, Michael Milovanov, Olga Shchagina, Anna Voronkova, Victoria Sherman, Stanislav Krasovsky et al. · 2026 · International Journal of Molecular Sciences
92. The dipeptidyl peptidase 1 inhibition landscape in bronchiectasis and its future direction
    James Duncan Chalmers, Raksha Jain, Anne E. O’Donnell, Marcus Alexander Mall, Patrick A. Flume · 2026 · European Respiratory Review
93. The “Selfish Cell”: The Central Role of Metabolism in Relaying Environmental Stimuli and Controlling Cellular Function
    Sabina Di Matteo, Davide Gnocchi · 2026 · Biology
94. Lung transplant perspectives in the era of elexacaftor/tezacaftor/ivacaftor (ETI): Navigating clinical uncertainty and ETI limbo among people with cystic fibrosis, a qualitative analysis
    Melissa J. Basile, Dave Young, Sierra Knapp, T. Milinic, Alexi L. Vasbinder, Lauren Bartlett, Rebecca Mueller, Andrea L. Hartzler, Donna Lynn Berry, Siddhartha G. Kapnadak et al. · 2026 · Heart & Lung
95. Triple combination ivacaftor + tezacaftor + elexacaftor and ivacaftor for cystic fibrosis: clinical efficacy and safety of the original drug and its generic analogue Trilexa®
    З. М. Мержоева, Iuliia A. Levina, Baina B. Lavginova, Olga Suvorova, Nataliya Y. Kashirskaya, Sergey Nikolaevich Avdeev · 2026 · PULMONOLOGIYA
96. Physiologically Based Pharmacokinetic Modeling of Elexacaftor–Tezacaftor–Ivacaftor in Adults and Pediatric People with Cystic Fibrosis: Exploring Brain Exposure and Neuropsychiatric Adverse Events
    Clotilde Vellat, Laurent Bourguignon, Sabine Cohen, Philippe Reix, Romain Garreau · 2026 · Clinical Pharmacokinetics
97. Emerging pharmacological therapies for bronchiectasis
    Meghan Marmor, Mark L. Metersky · 2026 · Expert Review of Clinical Pharmacology
98. Defective Inflammation Resolution in Cystic Fibrosis: Cellular Mechanisms and Emerging Pro-resolving Therapies in the CFTR Modulator Era
    Mario Romano, Simona D’Orazio, Domenico Mattoscio, Matteo Mucci, Roberto Plebani, Shameer Pillarisetti, Antonio Recchiuti · 2026 · Current topics in microbiology and immunology
99. Predictive Modeling of CFTR Modulator Efficiency: A Machine Learning Approach
    Sahasra Muchalapuri · 2026
100. Development and temporal evaluation of a multivariable prediction model to screen for late-diagnosed cystic fibrosis
     Richard Belkin, Yuri Matusov, Barry Belkin · 2026 · Research Square